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INTRODUCTION
Gastric cancer still remains the third cause of cancer death
in both genders and the fifth most incident cancer world-
wide (Ferlay et al., 2012). The World Health Organisation
(WHO) International Agency for Research on Cancer
(IARC) has recognised Helicobacter pylori (H. pylori) as a
Group-one carcinogen for gastric cancer development since
1994 (Anonymous, 1994). Nevertheless, only over 1–2% of
patients infected with H. pylori will develop gastric cancer
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Histamine has an important role in the process of the gastric mucosa inflammation acting via his-
tamine receptor H2 (encoded by the gene HRH2). Single nucleotide polymorphism of the
enhancer element of HRH2 gene promoter rs2067474 (1018 G > A) may be associated with
changes of expression of the receptor. We attempted to clarify the association of this polymor-
phism with gastric cancer and/or atrophic gastritis in the Latvian (Caucasian) population. The
study group consisted of 121 gastric cancer patients and 650 patients with no evidence of gastric
neoplasia on upper gastrointestinal endoscopy. Genotyping for rs2067474 was performed with
the TaqMan probe-based system using a commercially available probe for RT-PCR. The fre-
quency of the A allele in the gastric cancer group was 0.41% and in the control group — 1.54%
(p = 0.231). No significant differences were found comparing genotypes between gastric cancer
versus control patients (OR = 0.236, CI95% = 0.030–1.896), patients with (n = 165) versus with-
out (n = 485) gastric metaplastic lesions (OR = 0.854, CI95% = 0.288–2.540) and patients with
(n = 297) and without (n = 353) gastric atrophic lesions (OR = 1.145, CI95% = 0.451–2.906). Our
findings suggest that the HRH2 -1018 G > A polymorphism (rs2067474) is neither associated with
gastric cancer nor the grade of atrophic gastritis in the Latvian (Caucasian) population.
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during their lifetime (Parsonnet et al., 1991). Gastric cancer
pathogenesis is a complex process involving both host and
bacterial genetic factors, which play a role in the develop-
ment of the inflammation, epithelial transformation, etc.
(Wroblewski et al., 2010; Alzahrani et al., 2014). Many re-
cent studies have focused on the role of single nucleotide
polymorphisms (SNP) involved in the gastric carcinogene-
sis (Wroblewski et al., 2010), which are selected either
from genome-wide association studies or because the gene-
encoded product is or may be involved in gastric cancer
pathogenesis.
The gastrointestinal tract is rich in neuroendocrine cells pro-
ducing various hormones: G cells produce gastrin, D cells
produce somatostatin, enterochromaffin-like (ECL) cells
produce histamine and others (Ched et al., 2006).
Histamine-producing ECL cells are located in the oxyntic
mucosa of the stomach and have paracrine appearance
(Hananson et al., 1986). Histamine has various biological
effects acting via four types of histamine receptors (Hill et
al., 1997; de Ersh et al., 2005); stimulation of histamine H2
receptor (HRH2) plays a crucial role in the regulation of
gastric acid secretion (Hill et al., 1997; Ched et al., 2006).
Histamine has an important role in the process of the gastric
mucosa inflammation acting via HRH2, albeit H. pylori in-
fection is the major contributing factor in the development
of inflammation (McGowan et al., 1996).
The HRH2-encoding gene is located on the 5q35.2 chromo-
some. SNP of the enhancer element of the HRH2 gene pro-
moter rs2067474 results in the transition of –1018 G > A
and may be associated with changes of expression of the re-
ceptor (Guo et al., 2005). Currently, only few papers on the
association of HRH2 SNP rs2067474 with gastric mucosa
atrophy and gastric cancer have been published, in the Japa-
nese population by Arisawa’s group (Arisawa et al., 2012;
Yamada et al., 2012).
The aim of our study was to determine if there is an associa-
tion of HRH2 –1018 G > A (rs2067474) genotype with gas-
tric cancer and/or atrophic gastritis in the Latvian (Cauca-
sian) population, which has European ancestry.
MATERIALS AND METHODS
Study design. Gastric cancer patients (n = 121) from Rîga
East Clinical University Hospital (Latvia) with an estab-
lished diagnosis were invited to participate in the study.
Patients (n = 650) being referred for upper gastrointestinal
endoscopy to the outpatient department of Rîga East Clini-
cal University Hospital or Centre of Digestive Diseases
“GASTRO” (Latvia) due to dyspeptic symptoms were in-
cluded in the control group. The following exclusion criteria
were used: gastric lymphoma, gastric dysplasia, cancer of
the oesophagus, Barrett’s oesophagus and history of pre-
vious gastric surgery. All patients who participated in the
study were Caucasians. All patients were invited to partici-
pate in the study during the time period 2010–2014.
A blood sample with EDTA anticoagulant was taken from
each patient for DNA extraction with further genotyping.
DNA was extracted from whole blood using the phenol-
chlorophorm method. All control group patients underwent
upper gastrointestinal tract endoscopy with further histopa-
thological evaluation of the biopsies.
Upper gastrointestinal tract endoscopy. The upper gastro-
intestinal tract endoscopy was performed after night-time
fasting. Standard biopsy material from each patient was
taken during the procedure from at least five different loca-
tions in the stomach: two from corpus mucosa (one from the
lesser and one from the greater curvature), one from in-
cisura angularis mucosa (from the lesser curvature) and two
from antral mucosa (one from the lesser and one from the
greater curvature) (Dixon et al., 1996). Additional biopsies
were taken from any columnar-lined mucosa in the oe-
sophagus and sites suspicious for neoplastic lesions in the
stomach and oesophagus.
Histopathology. Three experienced expert gastrointestinal
pathologists, blinded to any clinical data, separately exam-
ined all the biopsies for controls. All histopathological find-
ings were reported separately for each biopsy site from the
stomach: corpus mucosa, incisura angularis mucosa and an-
trum mucosa. The slides were stained with hematoxylin-
eosin, Alcian blue and Giemsa. Metaplastic epithelial
changes, H. pylori colonisation and gastric mucosa atrophy
were scored using visual analogue scales (0 = absents, 1 =
mild, 2 = moderate, 3 = severe), according to the updated
Sydney classification system (Dixon et al., 1996). All re-
sults were transformed into the OLGIM and OLGA staging
systems (Rugge et al., 2013).
In case the difference in the evaluation scores of any posi-
tion by at least of two points was considered significant, all
such cases were reassessed by all three pathologists together
until consensus agreement was reached.
All histopathological slides from gastric cancer surgery
cases were reassessed by two expert gastrointestinal pa-
thologists. The slides were stained with hematoxylin-eosin.
Consensus agreement about each case was achieved. When-
ever proper morphological material was available (in accor-
dance to WHO standards) (Bosman et al., 2010), subtyping
according to the Lauren classification was done (Lauren,
1965).
Genotyping of polymorphisms. DNA was extracted by the
standard phenol-chloroform method. Genotyping for
rs2067474 (–1018 G > A) was performed with the TaqMan
Probe-based system (Applied Biosystems Inc., Carlsbad,
CA, USA) using a commercially available probe
(C_15859301_10) on an automatic sequence detection in-
strument (Real-Time PCR System, Applied Biosystems
Inc., Carlsbad, CA, USA). Reactions were carried out under
the standard conditions as recommended by the manufac-
turer.
Serology. Blood samples for serological evaluation were
taken prior to surgery (in gastric cancer patients) and prior
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to upper gastrointestinal endoscopy (in controls). Blood se-
rum was separated from the whole blood and stored frozen
at –80 oC in the laboratory. All serum samples were ana-
lysed using an enzyme-linked immunosorbent assay kit for
H. pylori detection (Helicobacter pylori EIA Test kit,
GastroPanel®, Biohit Oyj., Helsinki, Finland). Reactions
were carried out under the standard conditions as recom-
mended by the manufacturer. Patients were considered sero-
positive if the anti-H. pylori level was equal or higher than
30 EIU/mL.
Statistical analysis. Age was expressed as median and in-
terquartile range (IQR), the comparison between groups
was done using the Median test for independent samples.
Ratio of gender, H. pylori serology, H. pylori histology,
HRH2 gene alleles and genotypes were compared using the
Fisher’s exact test. Adjusted odds ratio (OR) and 95% con-
fidence interval (CI95%) were calculated using logistic re-
gression analysis. Allele and genotype frequencies were cal-
culated by direct count. The relationship of age with
OLGIM and OLGA stage in different genotypes was as-
sessed with the Spearman’s rank correlation coefficient (r2).
All analyses and charts were made using SPSS 20.0 soft-
ware (SPSS Inc., Chicago, IL, USA) and post hoc statistical
power estimation was done using the OSSE online calcula-
tor (http://osse.bii.a-star.edu.sg/calculation2.php).
Ethical considerations. The Central Medical Ethics Com-
mittee of Latvia (No A-11 (15.12.2010)) approved the study
protocol before patient recruitment was started. All the pa-
tients signed informed consent forms before the enrolment
according to the Helsinki declaration.
RESULTS
The characteristics of both study groups are shown in Table
1. Male/female ratio, mean age, and positive H. pylori serol-
ogy ratio were significantly higher in the gastric cancer pa-
tients. The AA genotype was not present in the gastric can-
cer group nor among the control group members. In the
control group, the AG genotype was found in 20 patients
and GG — in 630. It was in the Hardy-Weinberg equilib-
rium (p 0.05). The frequency of the A allele in the gastric
cancer group was 0.41% and in the control group — 1.54%.
There was no significant difference comparing genotype ra-
tios between both study groups (p = 0.228). After adjusting
for gender, age and H. pylori serology, no significant differ-
ence in genotype frequency was identified (OR = 0.236,
CI95% = 0.030–1.896, p = 0.176).
According to the Lauren classification, 61/121 patients had
intestinal type gastric cancer, 34/121 — diffuse, 18/121 —
mixed-type and 8/121 — indeterminate. In accordance to
the TNM classification, 25/121 patients had stage I disease,
37/121 — stage II disease, 52/121 — stage III disease,
4/121 — stage IV disease and for three patients, no data
was available (Edge et al., 2009). The only patient with the
AG genotype in the cancer group had mixed-type gastric
cancer and stage III disease.
The control group was subdivided into two groups accord-
ing to the OLGIM classification system: one group having
an OLGIM 0 stage (n = 485) and the other group having an
OLGIM I-IV stage (n = 165). The general characteristics of
those groups are shown in the Table 2. After adjusting for
T a b l e 1
CHARACTERISTICS OF STUDY GROUPS AND GENOTYPE FRE-




Number of subjects 121 650
Gender
male 73 (60.3%) 195 (30.0%) < 0.001a
female 48 (39.7%) 455 (70.0%)
Median of age (IQR),
years
65.0 (56.5-73.5) 49.0 (35.0-63.0) < 0.001b
H. pylori serology
positive 91 (75.2%) 367 (54.5%) < 0.001c
negative 30 (24.8%) 282 (45.5%)
on genotype
AA 0 0 0.228d
AG 1 20
GG 120 630
A allele frequency 0.41% 1.54% 0.231e
IQR, interquartile range; a ratio of gender between groups; b medians of
age between groups; c ratio of H. pylori serology between groups; d ratio of
AG and GG genotypes between groups; e ratio of A allele frequency be-
tween groups
T a b l e 2
CHARACTERISTICS OF THE CONTROL GROUP AND GENOTYPE
FREQUENCIES IN ACCORDANCE TO THE OLGIM CLASSIFICA-
TION
OLGIM I–IV OLGIM 0 p
Number of subjects 165 485
Gender
male 54 (32.7%) 141 (29.1%) 0.378a
female 111 (67.3%) 344 (70.9%)
Median of age (IQR),
years
59.0 (49.0-70.0) 44.0 (32.5-59.0) < 0.001b
H. pylori serology
positive 62 (37.6%) 220 (45.5%) 0.084c
negative 103 (63.4%) 265 (54.5%)
H. pylori histology
positive 96 (58.2%) 230 (47.4%) 0.019d
negative 69 (41.8%) 255 (52.6%)
HRH2 genotype
AA 0 0 1.000e
AG 5 15
GG 160 470
A allele frequency 1.51% 1.55% 1.000f
IQR, interquartile range; a ratio of gender between groups; b medians of
age between groups; c ratio of H. pylori serology between groups; d ratio of
H. pylori histology between groups; e ratio of AG and GG genotypes be-
tween groups; f ratio of A allele frequency between groups
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age and H. pylori histology, no significant difference was
identified in the genotypes (OR = 0.854, CI95% =
0.288–2.540, p = 0.778). Both groups had similar A allele
frequencies of 1.51% and 1.55%, respectively OLGIM I-IV
and OLGIM 0. All patients with the AG genotype in the
OLGIM I–IV subgroup had the OLGIM I stage. There were
110 patients with OLGIM stage I, 32 — with stage II, 13 —
with stage III and five — with stage IV.
In addition, the control group was subdivided into two
groups according to the OLGA stage classification system:
one group having the OLGA stage 0 (n = 353) and the other
group having the OLGA stage I–IV (n = 297). The general
characteristics of those groups are shown in Table 3. After
adjusting for age, H. pylori serology and H. pylori histol-
ogy, no significant difference was identified in the geno-
types (OR = 1.145, CI95% = 0.451–2.906, p = 0.776). Both
groups had similar A allele frequencies of 1.42% and
1.68%, respectively, OLGA stage I–IV and OLGA stage 0.
All patients (n = 10) with the AG genotype in the OLGA
stage I–IV subgroup had the OLGA stage I. There were 233
patients with OLGA stage I, 41 — with stage II, 17 — with
stage III and six — with stage IV.
In the control group patients with the GG genotype had an
increase of both OLGIM and OLGA stage with age (see
Figure 1 and Figure 2, respectively), respectively r2 = 0.332
(p < 0.001) and r2 = 0.299 (p < 0.001). No significant dif-
ference was found in patients with the AG genotype.
Post hoc statistical power estimation (desired significance
level 0.05) was done. Statistical power of A allele frequency
and gastric cancer was 21.1%.
DISCUSSION
Several reports on the role of HRH2 –1018 G > A
(rs2067474) polymorphism in the risk of human disease de-
velopment are currently available. Many reports are focused
on the association of HRH2 –1018 G > A polymorphism
and diseases of the central nervous system (Mancama et al.,
2002; Garcia-Martin et al., 2008) and breast cancer (Cai et
al., 2015). However, only a few studies have addressed the
potential associations to gastric precancerous lesions, i.e.
atrophic gastritis (Arisawa et al., 2012; Yamada et al.,
2012), and the only study addressing the association to gas-
tric cancer was the one by Arisawa et al. (2012).
T a b l e 3
CHARACTERISTICS OF THE CONTROL GROUP AND GENOTYPE
FREQUENCIES IN ACCORDANCE TO THE OLGA STAGE CLASSI-
FICATION
OLGA I–IV OLGA 0 p
Number of subjects 297 353
Gender
male 78 (26.3%) 117 (33.1%) 0.059a
female 219 (73.7%) 236 (66.9%)
Median of age (IQR),
years
59.0 (45.0-69.0) 43.0 (32.0-58.0) < 0.001b
H. pylori serology
positive 104 (35.0%) 178 (50.6%) < 0.001c
negative 193 (65.0%) 174 (49.4%)
H. pylori histology
positive 173 (58.2%) 153 (43.3%) < 0.001d
negative 124 (41.8%) 200 (56.7%)
HRH2 genotype
AA 0 0 0.821e
AG 10 10
GG 287 343
A allele frequency 1.68% 1.42% 0.822f
IQR, interquartile range; a ratio of gender between groups; b medians of
age between groups; c ratio of H. pylori serology between groups; d ratio of
H. pylori histology between groups; e ratio of AG and GG genotypes be-
tween groups; f ratio of A allele frequency between groups
Fig. 1. Relationship of OLGIM stage and age in patients with the GG ge-
notype.
Fig. 2. Relationship of OLGA stage and age in patients with the GG geno-
type.
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In our study, we were unable to identify any significant dif-
ferences in the distribution of HRH2 –1018 G > A genotype
among gastric cancer patients in comparison to patients
with no gastric cancer. There was also no difference ob-
served when comparing patients with intact gastric mucosa
to patients with atrophic gastritis. In the study of Arisawa
there was a significant association of gastric cancer and
HRH2 –1018 G > A polymorphism, and A allele presence
was considered as a protective factor for gastric cancer (Ari-
sawa et al., 2012). The positive result of the study partially
may be explained by the higher frequency of the A allele in
the Japanese population.
The HRH2 –1018 A allele frequency in Latvian non-gastric
cancer patient group was 1.54% only. That is lower than in
the patient sample from Arisawa’s study (13.5%) (Arisawa
et al., 2012) and also lower than in healthy Spanish popula-
tion (5.0%) (Garcia-Martin et al., 2008). There are known
differences among populations in the A allele frequency,
e.g., the 1000 Genomes Project data showed a general fre-
quency in European populations of 4% (ranging from 3.3%
in the Iberian population of Spain to 5.6% in Finland) and
in Eastern Asians — 13.9% (from 9.6% in Japanese
from Tokyo to 17% in Han Chinese in Beijing, China)
(www.1000genomes.org) (Auton et al., 2015).
The main limitation of the study was the small statistical
power on the post hoc analysis due to a very small fre-
quency of the A allele in the Latvian population. Some
other limitations of the study were male/female ratio; mean
age and positive H. pylori serology ratio were significantly
higher in the gastric cancer patients. For this reason, adjust-
ment for these factors was done, but still no significant dif-
ference among genotype distribution was identified. An-
other limitation was that the control group patients were
represented by the population of patients with various
symptoms from the upper digestive tract.
In our study, we did not observe any association of HRH2
–1018 G > A polymorphism with different OLGIM and
OLGA stages. The A allele frequency was similar in pa-
tients with intact gastric mucosa compared to patients with
changes of various degrees in gastric mucosa. However, we
could identify only a weak correlation of age with OLGA
and OLGIM score in non-gastric cancer patients with GG
genotype. Even so, one Japanese group published several
reports, where a significant association of GG genotype
with metaplasia and/or atrophy of gastric mucosa was found
in persons older than 60 years (Arisawa et al., 2012; Ya-
mada et al., 2012).
Many publications (Lampiasi et al., 2007; Gricco et al.,
2008) are available regarding the role of histamine in the
development of gastrointestinal cancers. The SNP of the en-
hancer element of the HRH2 gene promoter rs2067474 may
be associated with changes of expression of the receptor
and/or function of HRH2. In experimental models with gas-
tric cancer cell lines, it was found that stimulation of HRH2
stimulates an increase of cAMP production (Ermani et al.,
1983), which in advance stimulates the growth of gastric
cancer (Kong et al., 2012). It was also found that the
rs2067474 GG homozygote is associated with CDH1 and
DAPK methylation, which is crucial for gastric carcino-
genesis (Nomura et al., 2013). Even so, the current data
available do not identify the precise role of HRH2 –1018
G > A (rs2067474) polymorphism in the gastric carcino-
genesis.
In conclusion, our findings suggest that the HRH2 –1018
G > A polymorphism (rs2067474) is neither associated with
gastric cancer nor the grade of atrophic gastritis in the Lat-
vian (Caucasian) population. The frequency of the A allele
in the Latvian (Caucasian) population is extremely different
from the Japanese population and is the lowest among Euro-
pean populations. Future epidemiological studies are needed
based on a larger sample size in populations with very low
A allele frequency, such as the Latvian population, includ-
ing at least 1500 patients in each group, to determine if the
HRH2 –1018 G > A polymorphism (rs2067474) is associ-
ated with gastric cancer.
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NAV SAISTÎBAS STARP HISTAMÎNA H2 RECEPTORA GÇNA POLIMORFISMU RS2067474 UN KUÒÌA VÇZI LATVIJAS
POPULÂCIJÂ
Histamînam, mijedarbojoties ar histamîna H2 receptoru (kodç HRH2 gçns), ir svarîga loma kuòìa gïotâdas iekaisuma procesa attîstîbâ.
Polimorfisms rs2067474 – (–1018 G A) HRH2 gçna promotera pastiprinâtâjâ var bût saistîts ar izmaiòâm receptora ekspresijâ. Pçtîjumâ
mçìinâts noskaidrot ðî polimorfisma saistîbu ar kuòìa vçzi un/vai atrofisku gastrîtu Latvijas populâcijâ. Pçtîjumâ iesaistîti: 121 kuòìa vçþa
pacients un 650 pacienti bez kuòìa vçþa, izmeklçjot ar augðçjo kuòìa zarnu trakta endosksopiju. Genotipçðana rs2067474 veikta ar TaqMan
zondçm. A alçles bieþums kuòìa vçþa pacientiem bija 0,41%, kontroles grupas pacientiem — 1,54% (p = 0,231). Nozîmîgas atðíirîbas,
salîdzinot kuòìa vçþa un kontroles pacientu genotipus, netika atrastas (OR = 0,236, CI95% = 0,030–1,896). Atðíirîbas netika atrastas,
salîdzinot pacientu genotipus ar kuòìa gïotâdas metaplâziju (n = 165) un bez kuòìa gïotâdas metaplâzijas (n = 485) (OR = 0,854, CI95% =
0,288–2,540); un pacientus ar kuòìa gïotâdas atrofiju (n = 297) un bez tâs (n = 353) (OR = 1,145, CI95% = 0,451–2,906). HRH2 gçna –
1018 G > A polimorfisms (rs2067474) nav saistîts ne ar kuòìa vçzi, ne ar atrofiska gastrîta pakâpi Latvijas populâcijâ.
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